echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Active Ingredient News > Antitumor Therapy > NEJM: The effect of anti-B cell maturation antigen CAR-T cell therapy bb2121 in the treatment of multiple myeloma

    NEJM: The effect of anti-B cell maturation antigen CAR-T cell therapy bb2121 in the treatment of multiple myeloma

    • Last Update: 2021-05-20
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

    bb2121 is a chimeric antigen receptor (CAR) T cell therapy against B cell maturation antigen (BCMA).


    The study included patients with relapsed or refractory multiple myeloma.


    6 6 6 6 6 6 Immunity

     

    The study reported the results of 33 consecutive patients who received the earliest input of bb2121.


     

    During the trial, a total of 25 patients (76%) developed cytokine release syndrome, of which 23 cases (70%) were grade 1 or 2, and 2 cases (6%) were grade 3.


     

    The median progression-free survival was 11.


    In summary, the study reported the preliminary toxicity characteristics of patients with relapsed or refractory multiple myeloma after receiving cellular immunotherapy targeting BCMA, and the study confirmed the anti-tumor activity of bb2121.


     

    Original source:

     

    Noopur Raje, et al.


    ncbi.
    nlm.
    nih.
    gov/31042825/" target="_blank" rel="noopener">Anti-BCMA CAR T-Cell Therapy bb2121 in Relapsed or Refractory Multiple Myeloma

    in this message
    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.